NXL · XBRL financial data

Nexalin Technology financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NXL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	24	21*	79	27	36	27*	41	71	18	year only	15	12
Cost of revenue	4	5*	9	7	13	7*	14	23	4	21*	2	3
Gross profit	20	15*	70	20	23	20*	27	48	14	—	13	9
Research and development	1,639	80*	106	169	179	737*	406	226	227	225*	346	564
Selling, general and administrative	1,945	1,049*	589	768	1,975	896*	929	894	1,420	1,155*	793	783
General and administrative	—	year only	646	594	548	766*	623	687	780	1,043*	802	853
Total operating expenses	2,436	1,640*	1,143	1,317	2,532	2,895*	2,039	1,669	2,360	2,564*	2,133	2,256
Operating income (loss)	(2,416)	(1,624)*	(1,074)	(1,297)	(2,509)	(2,875)*	(2,011)	(1,621)	(2,346)	(2,413)*	(2,120)	(2,247)
Interest expense	5	19*	(0)	(0)	(1)	(2)*	(1)	(5)	(2)	(0)*	(0)	(0)
Net income (loss)	(2,297)	(781)*	(1,041)	(1,284)	(2,448)	(2,833)*	(1,988)	(1,581)	(2,276)	(2,377)*	(2,097)	(2,239)
Earnings per share, basic USD per share	(0.31)	(0.10)*	(0.14)	(0.17)	(0.23)	(0.26)*	(0.15)	(0.10)	(0.13)	(0.13)*	(0.11)	(0.11)
Earnings per share, diluted USD per share	(0.31)	(0.10)*	(0.14)	(0.17)	(0.23)	(0.26)*	(0.15)	(0.10)	(0.13)	(0.13)*	(0.11)	(0.11)
Weighted average shares, basic thousands of shares	7,415	7,437*	7,437	7,498	10,847	11,043*	13,307	15,718	17,794	18,676*	19,821	21,143
Weighted average shares, diluted thousands of shares	7,415	7,437*	7,437	7,498	10,847	11,043*	13,307	15,718	17,794	18,676*	19,821	21,143

Fiscal quarters (NXL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	361	580	546	849	81	574	622	431	590	655	1,208	1,005
Short-term investments	3,576	2,368	1,598	—	4,512	2,905	1,429	5,361	3,763	3,068	1,501	—
Accounts receivable	14	9	4	12	15	13	14	60	8	82	43	53
Inventory	159	156	154	145	158	175	175	173	160	131	179	233
Prepaid and other current assets	153	316	262	176	140	294	380	244	297	363	359	571
Total current assets	4,263	3,430	2,563	1,182	4,908	3,961	2,621	6,269	4,817	4,299	3,290	1,862
Property and equipment, net	0	—	—	—	—	—	—	—	—	—	—	42
Right-of-use asset	2	0	—	—	—	—	—	—	—	—	—	—
Total assets	4,434	3,632	2,834	1,563	5,257	4,223	2,900	6,564	5,126	4,635	3,695	3,004
Accounts payable	73	160	152	87	167	156	181	241	67	245	168	239
Accrued liabilities	607	261	356	125	133	391	393	360	290	643	640	859
Total current liabilities	1,197	425	507	212	299	547	575	601	358	887	808	1,485
Total liabilities	1,197	425	507	212	299	547	575	601	358	887	808	1,485
Accumulated deficit	(76,257)	(77,038)	(78,079)	(79,364)	(81,812)	(84,645)	(86,634)	(88,215)	(90,491)	(92,867)	(94,964)	(97,203)
Total stockholders' equity	3,237	3,207	2,327	1,351	4,958	3,676	2,325	5,963	4,768	3,748	2,886	1,519
Total liabilities and equity	4,434	3,632	2,834	1,563	5,257	4,223	2,900	6,564	5,126	4,635	3,695	3,004
Common shares outstanding (cover page) thousands of shares	7,437	7,437	7,437	10,587	12,862	13,304	17,178	17,418	18,652	20,582	20,582	22,036

Fiscal quarters (NXL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,297)	(781)*	(1,041)	(1,284)	(2,448)	(2,833)*	(1,988)	(1,581)	(2,276)	(2,377)*	(2,097)	(2,239)
Stock-based compensation	1,573*	752*	161	308*	1,539*	1,552*	637	572*	1,083*	832*	479	408*
Net cash from operating activities	(701)*	(1,004)*	(763)	(1,246)*	(800)*	(1,134)*	(1,426)	(917)*	(1,466)*	(1,148)*	(1,713)	(1,802)*
Net cash from investing activities	831*	1,223*	729	1,549*	(4,483)*	1,628*	1,474	(3,920)*	1,625*	689*	1,510	1,460*
Proceeds from issuing common stock	—	—	—	—	—	0*	—	—	0*	0*	—	—
Net cash from financing activities	0*	0*	—	—	—	0*	—	—	0*	524*	756	138*

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Nexalin Technology	1,005	12	(1,802)*	22.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Iridex	4,680	12,566	174*	17.6M	—	Q2 FY26 10-QJul 4, 2026
Beyond Air	5,509	1,768	(4,946)	957,631	2.0 quarters	Q1 FY27 10-QJun 30, 2026
RetinalGenix Technologies	27	not reported	(137)*	18.8M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Harvard Apparatus Regenerative Technology	351	414	(569)*	17.6M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026
Envoy Medical	19,679	51	(5,456)*	77.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
PetVivo Holdings	123	338	(966)	38.0M	0.1 quarters	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.